KRAS and colorectal carcinoma: The ORR specifically among patients with CRC (n=20) receiving LY3537982 as monotherapy was 10%, compared to 42% among those with pancreatic (n=12) or 38% in NSCLC not previously treated with a KRAS G12C inhibitor (n=8).